CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting

Phase 1

CD40 Agonist, Flt3 Ligand, ChemotherapyCD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Sponsor:

University of Texas Southwestern Medical Center

Code:

NCT05029999

Conditions

HER2-negative Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

PLD Chemotherapy

CDX-1140

CDX-301

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-04. This information was provided to ClinicalTrials.gov by University of Texas Southwestern Medical Center on 2025-08-13.